FIELD: biotechnology.
SUBSTANCE: disclosed are the use of a combination drug for treating solid cancer in a subject containing a T-cell expressing interleukin-7, CCL19 (chemokine ligand 19 with motif C-C) and a chimeric antigen receptor (CAR) or a T-cell receptor (TCR), which specifically recognizes a cancer antigen and an immunosuppression inhibitor, where the immunosuppression inhibitor is an IgG monoclonal antibody or a fragment thereof, a drug for treating solid cancer containing an interleukin-7 expressing T cell, CCL19 and a chimeric antigen receptor (CAR) or T-cell receptor (TCR), which specifically recognizes a cancer antigen, a kit and a pharmaceutical composition for use in treating solid cancer in a subject, comprising a container containing a drug. Also disclosed is a T-cell expressing interleukin-7, CCL19, a polypeptide which inhibits immunosuppression, and a chimeric antigen receptor (CAR) or a T-cell receptor (TCR) which specifically recognizes a cancer antigen, comprising nucleic acids coding interleukin-7, CCL19, an immunosuppression-inhibiting polypeptide, and a chimeric antigen receptor (CAR) or a T-cell receptor (TCR), which specifically recognizes a cancer antigen, and a drug for treating solid cancer containing said T cell.
EFFECT: group of inventions is used to treat solid cancer in a subject.
19 cl, 17 dwg, 1 ex
